Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.